The Food and Drug Administration approval of 2 blood tests to detect amyloid plaques marks a breakthrough moment for Alzheimer disease.1 Compared with diagnostics based on cerebrospinal fluid or positron emission tomography imaging, blood biomarkers are much more accessible and provide a more streamlined path to potential treatments and clinical trials. Yet, the growing enthusiasm for biomarkers risks obscuring a fundamental truth: biomarkers only reflect disease pathology.